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Abstract: The strategic design of most insulin sensitivity (SI) tests maximises either accuracy or 
economy, but not both. Hence, accurate, large-scale screening isn’t feasible. The DIST was developed to 
better optimize both important metrics. The highly flexible DIST protocol samples insulin, glucose and 
C-peptide during a comparatively short test. Varying the sampling periods and assays, and utilising 
alternative computational methods enables a wide range of tests with different accuracy and economy 
tradeoffs. The result is a hierarchy of tests to facilitate low-cost screening. 
Eight variations of the DIST are evaluated against the fully-sampled test by correlating the SI and 
endogenous insulin production (Uen(t)) metrics. Five variations include sample and assay reductions and 
three utilise DISTq parameter estimations. The DISTq identification methods only require glucose assays 
and thus enable real-time analysis. Three DISTq methods were tested; the fully-sampled, the Short, and 
the 30 minute two-sample protocol. 218 DIST tests were completed on 84 participants to provide the data 
for this study. 
Methods that assayed insulin replicated the findings of the full DIST particularly well (R=0.89~0.92) 
while those that assayed C-peptide managed to best replicate endogenous insulin metrics (R=0.72~1.0). 
The three DISTq protocols correlated to the fully-sampled DIST at R=0.83, 0.77 and 0.71 respectively. 
As expected, test resolution increased with rising protocol cost and intensity. The ability of significantly 
less expensive tests to replicate the values of the fully-sampled DIST was relatively high (R=0.92 with 
four glucose and two insulin assays and 0.71 with only two glucose assays). Thus, an SI screening 
programme could achieve high resolution at a low cost by using a lower resolution DIST test. When an 
individual’s result is close to a diagnostic threshold stored test samples could be re-assayed for more 
species to allow a higher resolution analysis without the need for a second invasive clinical test. Hence, a 
single test can lead to several outcomes with this hierarchy approach, enabling large scale screening with 
high resolution only where required with minimal and feasible economic cost and only a single invasive 
clinical procedure. 
Keywords: Physiological Models, Parameter Identification, Diagnostic Tests, Dynamic Tests. 
1. INTRODUCTION 
Numerous investigations have found that insulin sensitivity 
(SI) is an important metabolic marker (Hanley et al. 2005; 
McLaughlin et al. 2007; Santaguida et al. 2005; Zimmet et al. 
1999) and type 2 diabetes risk evaluator (DeFronzo & 
Ferrannini 1991; Ferrannini 1997; Harris et al. 2003; Martin 
et al. 1992). Generally, SI tests have either intense high-cost 
protocols that enable high resolution identification of SI, or 
lower intensity protocols that provide lower accuracy and 
cost (Ferrannini & Mari 1998; Pacini & Mari 2003). 
Our group has previously presented the dynamic insulin 
sensitivity test (DIST) that was designed to fill the space 
between these contrasting design strategies (Lotz 2007; Lotz 
et al. 2008; McAuley et al. 2007). The DIST is a low-dose, 
short duration insulin-modified intra-venous glucose 
tolerance test, with comparatively infrequent sampling of 5-
10 minutes (N<10). A pharmaco-kinetic/dynamic 
physiological (PK/PD) model uses insulin, glucose and C-
peptide assays obtained during the DIST to identify 
participant-specific metrics for SI, first-pass liver extraction 
of insulin (xL), liver clearance of plasma insulin (nL) and 
endogenous insulin production profiles (Uen(t)). The Uen(t) 
profile yields valuable insight to the participant’s beta-cell 
health, which is a critical aspect of the pathogenesis of type 2 
diabetes (Ferrannini & Mari 2004; Pacini & Mari 2003). 
The DISTq method is an evolution of the DIST identification 
method that utilises novel population based parameter 
estimations of insulin secretion and kinetics to identify SI in 
the absence of insulin or C-peptide assays (Docherty et al. 
2009). It enables real-time analysis of SI because it uses only 
anatomical and glucose data that can be rapidly assayed at the 
place of testing. It is a faster, much less costly, but also less 
accurate test for SI screening. 
  
     
 
A range of DIST and DISTq protocols could be designed to 
occupy the space between the fully-sampled DIST and the 
DISTq. Investigation of these variations would identify how 
many samples are required for accurate identification of SI 
and Uen(t). This article presents and evaluates a spectrum of 
tests between the fully-sampled DIST and the DISTq with 
further extrapolations to extremely sparsely sampled tests. 
The overall outcome is a hierarchy of DIST-derived 
screening tests. A major advantage is that this hierarchy 
requires only one test per participant. When a participants 
result from a less expensive test is close to a threshold, stored 
blood samples can be re-assayed for different species to 
provide sufficient data for higher resolution and cost DIST 
identification methods. Thus, this approach enables screening 
at a low cost, but with high resolution.  
2. METHOD 
2.1 Participants 
Eighty-two female participants from the Otago region of New 
Zealand took part in a longitudinal intervention investigation 
(ref). All participants had characteristics associated with an 
increased risk of developing T2DM (BMI, family history 
and/or ethnicity). In total, 218 full DIST tests were performed 
at 0, 4 and 10 weeks of a macro-nutrient intervention. Full 
details on participant demographics and study design can be 
seen in (TeMorenga et al. 2010). 
2.2 Full DIST test protocol 
Participants attended the place of testing in the morning after 
an overnight fast. Age, weight and height were recorded and 
signed informed consent was obtained prior to the first test. 
Weight was recorded prior to each subsequent test. The 
University of Otago Human Ethics Committee granted 
approval for this study. 
Participants reported to the place of testing in the morning 
after an overnight fast. A canulla was placed in the 
antecubital fossa (a large vein in the inner elbow) for 
sampling blood and delivering boluses. Blood was sampled at 
t=0, 10, 15, 20, 25, 30, 35, 40, and 50 minutes. 10g glucose 
(50% dextrose) and 1U insulin (Actrapid
TM
) were 
administered immediately after the t=10 and 20 minute 
samples respectively. Blood samples were assayed for 
glucose immediately, then spun and frozen for later insulin 
and C-peptide assays. 
 2.3 Design strategy of the various proposed protocols 
Eight (reduced) variations of the DIST test protocol are 
evaluated by their ability to re-identify the SI value identified 
by the fully-sampled DIST. Each variation has differing 
advantages in terms of sample and cost reduction, with 
resulting different test resolutions. The 5 test protocols that 
utilise the DISTq (Docherty et al. 2009) identification 
methods limit the availability of patient-specific xL, nL and 
Uen(t) values. The sampling protocols, assay schedules, 
relative costs, and diagnostic parameters of the various tests, 
including HOMA and the fully-sampled DIST protocol, are 
defined in Table 1: 
Fully-sampled: The fully-sampled protocol was designed by 
our group and is detailed in Lotz et al. (Lotz 2007; Lotz et al. 
2008). It utilises all of the assay species (C-peptide, insulin 
and glucose) for every available sample time. 
Short: The Short protocol was designed to capture all major 
dynamics of the three species with reduced test time and 
samples. 
DIST-E/SI: The DIST-E/SI protocol was designed to enable 
accurate identification of SI and participant-specific Uen(t) 
metrics, while minimising sample assay cost. There are three 
significant metrics from a typical Uen(t) profile, the basal 
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Fully-
sampled 
GIC GIC GIC GIC GIC GIC GIC GIC GIC 9 9 9 $562 N Y 
Short - GIC GIC GIC - GIC - GIC - 5 5 5 $312 N Y 
DIST-E/SI - GIC GIC GI G GIC GI GI - 6 6 3 $270 N Y 
Sparse - GIC GIC - - - GIC - - 3 3 3 $187 N Y 
DIST-SI - GI I GI G GI GI GI - 6 6 0 $165 N N 
DIST-SI-2 - G - G - GI - GI - 4 2 0 $60 N N 
DISTq-FS G G G G G G G G G 9 0 0 $22 Y N 
DISTq-S - G G G - G - G - 5 0 0 $12 Y N 
DISTq-30 - G - - - - - G - 2 0 0 $5 Y N 
HOMA - GI - - - - - - - 1 1 0 $27 N N 
Table 1. DIST sampling schedules for the estimation of SI. G, I and C represent glucose, insulin and C-peptide assays. 
Italics show a sample ignored by the specific test’s parameter identification method but which may allow identification 
methods from other DIST protocols. Sample costs are estimated in NZD$ (glucose-$2.50, insulin-$25 and C-peptide-$35). 
The final columns show which protocols allow real-time analysis and participant-specific Uen(t) profiles. 
  
  
     
 
production rate (Ub), the peak first-phase secretion (UM), and 
the second-phase production (US). The three C-peptide assays 
chosen are the minimum possible to uniquely identify these 
three metrics. 
Sparse: The Sparse protocol significantly limits the number 
of assays, minimising clinical intensity. Only three samples 
are taken, which can be used to define the three major Uen(t) 
metrics and a SI. The second sample is taken 5 minutes after 
the glucose bolus, and the glucose concentration at this point 
is affected by mixing and is not used (Edsberg et al. 1987; 
Lotz 2007). Instead, the glucose bolus magnitude and 
population estimates of glucose distribution volume are used 
to define the concentration increase caused by the glucose 
bolus. 
DIST-SI: The DIST-SI protocol, identifies only SI, without 
any participant-specific Uen(t) metrics. Thus, no C-peptide, 
measurements are taken. The DISTq population-based 
parameter estimations (Docherty et al. 2009) are used to 
define the Uen(t) profile instead. 
DIST-SI-2: The DIST-SI-2 further reduces assays and 
clinical intensity by taking less samples and performing less 
assays than the DIST-SI protocol. The period of greatest 
importance to SI identification is the later part of the test 
protocol. Thus, only the two samples taken at the end of the 
test are assayed for insulin, while the full glucose response is 
identified with the four glucose assays.  
DISTq-FS: The DISTq-FS utilises all of the available 
glucose samples to define SI in an iterative process. The 
method utilises only glucose samples and anatomical data to 
identify a SI. The DISTq-FS has been shown to replicate 
fully-sampled DIST SI values (Docherty et al. 2009; 
Docherty et al. 2010). That analysis is repeated here in brief 
to allow a complete comparison.  
DISTq-S: This protocol mirrors the Short DIST and uses 
only four glucose samples to define a value for SI. The 
second glucose sample (at t=15) is not used by the 
identification method. However, taking this sample may 
allow for later analysis of the other species to obtain metrics 
for first-phase insulin production or to increase resolution of 
the result in a possible hierarchy of tests. 
DISTq-30: The DISTq-30 aims to identify SI from very 
sparse data. Only two glucose samples are taken. 
2.4 Test Hierarchy 
The sampling schedule of the various protocols could allow 
more, or less, assays from the samples taken during one test 
to enable differing analyses. For example, the sampling 
protocol of the DIST-SI could be followed yielding 7 blood 
samples. Assaying only 2-4 of them would enable a DISTq-
30 or DISTq-S analysis. However, if greater resolution were 
required to obtain an accurate diagnosis, stored samples could 
be re-assayed for insulin and/or C-peptide, as well as glucose 
where not done previously, to obtain a DIST-SI or Short 
DIST result (with Uen(t) metrics). 
This approach increases storage, but minimises cost for 
participants who can be diagnosed with a lower resolution 
test. Additionally only one clinically invasive procedure is 
required for the participant. Table 2 shows all the potential 
outcomes for each sampling protocol defined. 
Protocol 
completed 
Analyses possible with samples 
F
u
ll
y
-s
am
p
le
d
 
S
h
o
rt
 
D
IS
T
-E
/S
I 
S
p
ar
se
 
D
IS
T
-S
I 
D
IS
T
-S
I-
2
 
D
IS
T
q
-F
S
 
D
IS
T
q
-S
 
D
IS
T
q
-3
0
 
Fully-
sampled 
-  Y Y Y Y Y Y Y Y 
Short N - N N N Y N Y Y 
DIST-E/SI N Y - Y N Y N Y Y 
Sparse N N N - N N N N N 
DIST-SI N Y Y Y - Y N Y Y 
DIST-SI-2 N N N N N - N Y Y 
DISTq-FS Y Y Y Y Y Y - Y Y 
DISTq-S N Y N N N Y N - Y 
DISTq-30 N N N N N N N N - 
Table 2. Potential for different assay regimes to allow 
analyses with identification methods from other protocols. 
2.5 Identification methods of the proposed protocols 
The Uen(t) profiles for the various protocols are either 
defined using deconvolution (DC) or the population based 
estimates of the DISTq method (EDISTq). The deconvolution 
method was developed by Eaton et al. (Eaton et al. 1980) and 
validated by Van Cauter et al. (Van Cauter et al. 1992). It has 
previously been used with the DIST (Lotz 2007; Lotz et al. 
2008; McAuley et al. 2007). The DISTq methods and the 
population based estimates have been published previously 
(Docherty et al. 2009; Docherty et al. 2010). The final blood 
sample of the DIST-E/SI is not assayed for C-peptide, and the 
Uen(t) rate is assumed to be constant from the final point. 
Insulin concentrations in the plasma and interstitium are 
either defined using the iterative integral method (IIM) 
(Docherty et al. 2009; Hann et al. 2005) or the DISTq 
methods. (The DIST-SI-2 uses the DISTq parameter 
estimation for basal insulin (Ib), and IMM to identify nL with 
a fixed xL) 
Protocols which require DISTq parameter estimations for nL, 
have xL fixed at an average population value of 70% (Cobelli 
et al. 1998; Ferrannini & Cobelli 1987; Meier et al. 2005; 
Toffolo et al. 2006). Glucose related parameters are identified 
with the iterative integral method. The Sparse and DISTq-30 
protocols do not have sufficient glucose data to identify the 
volume of glucose distribution (Vg). In these cases, it is 
estimated as a proportion (29%) of the lean body mass as 
calculated by (Hume 1966).  
Table 3 summarises for which protocol each identification 
method is used. 
  
     
 
 Uen(t) Insulin Glucose 
Fully-
sampled 
DC IIM IIM 
Short DC IIM IIM 
DIST-E/SI DC* IIM IIM 
Sparse DC IIM IIM* 
DIST-SI EDISTq IIM IIM 
DIST-SI-2 EDISTq IIM-EDISTq* IIM 
DISTq-FS EDISTq EDISTq IIM 
DISTq-S EDISTq EDISTq IIM 
DISTq-30 EDISTq EDISTq IIM* 
Table 3. Identification methods for the various protocols. * 
indicates that the identification method must be adjusted to 
account for sparse sampling. 
2.6 Analysis 
The SI, Ub, UM and US values from the protocols are 
compared to the same values obtained from the fully-sampled 
DIST protocol using Pearson’s correlation coefficients and 
the gradients of the regression lines. The gradients allow a 
comparison of the proportional shift of identified metrics. 
The liver clearance of insulin parameters (nL, xL) have limited 
clinical diagnostic use and are not presented. Equation 1 is 
used to force the regression line through the origin to obtain a 
true proportional ratio between metric values (V) from the 
any given protocol: 
 
22
edfullysamplgiven VVG . (1) 
The homeostasis assessment model (HOMA) is also 
compared to the fully sampled DIST as it is an established, 
sparsely sampled fasting metric. 
3. RESULTS 
Table 4 summarises the performance of all the proposed 
protocols with respect to their ability to replicate the SI and 
Uen(t) values identified using the fully-sampled DIST.  
The sparser DIST-SI-2 method showed the greatest ability to 
replicate the SI metrics of the fully-sampled DIST by a small 
margin. It was closely followed by DIST-SI, the Short 
protocol, DIST-E/SI and the Sparse protocol. DISTq methods 
showed an expected, lesser ability to replicate SI. However, 
DISTq results were in line with previous findings (Docherty 
et al. 2009; Docherty et al. 2010) and represent a sound 
result.  
DISTq-S and DISTq-30 correlated highly to DISTq-FS: 
R=0.938 and R=0.893 respectively. When considering the 
vast reduction in samples between the DISTq-FS and DISTq-
30, R=0.893 indicates strong stability and robustness. 
Protocols that sampled basal and first-phase C-peptide 
showed absolute equivalence Ub and UM from the fully- 
sampled DIST. Reducing the number of C-peptide samples 
had a greater effect on US. The DISTq population estimates 
were strongest for US, weaker for Ub, and poor for UM, 
although the gradient of 0.8 implies that the general 
magnitude of the UM predictions were accurate.  
HOMA showed a relative inability to replicate the insulin 
sensitivity metrics of the fully sampled DIST. 
 SI 
R(G) 
Ub 
R(G) 
UM 
R(G) 
US 
R(G) 
DIST 1(1) 1(1) 1(1) 1(1) 
Short 
0.904 
(1.17) 
1(1) 1(1) 
0.885 
(0.99) 
DIST-E/SI 
0.901 
(1.10) 
1(1) 1(1) 
0.716 
(1.12) 
Sparse 
0.888 
(1.03) 
1(1) 1(1) 
0.881 
(0.95) 
DIST-SI 
0.908 
(1.10) 
0.622 
(0.94) 
0.073 
(0.80) 
0.751 
(0.90) 
DIST-SI-2 
0.922 
(1.07) 
0.683 
(0.97) 
0.09 
(0.81) 
0.736 
(0.99) 
DISTq-FS 
0.834 
(1.10) 
0.563 
(0.94) 
-0.074 
(0.80) 
0.697 
(0.90) 
DISTq-S 
0.767 
(1.27) 
0.526 
(0.92) 
-0.137 
(0.80) 
0.692 
(0.89) 
DISTq-30 
0.713 
(1.24) 
0.527 
(0.98) 
-0.143 
(0.80) 
0.708 
(1.04) 
HOMA 
-0.351 
(-) 
- - - 
Table 4. Ability of protocols to replicate SI and Uen(t) 
values from the fully-sampled DIST. 
4. DISCUSSION 
Relatively high correlations (R~0.9) between protocols that 
assayed insulin and the fully-sampled test show that the 
limited sampling protocols could be used as surrogates for 
the fully-sampled test without significantly diminishing test 
resolution. In particular, only three samples during a 25 
minute protocol in the Sparse protocol correlated relatively 
well to the fully-sampled test (R=0.888) and captured all 
major dynamics of the Uen(t) profile. 
DISTq results also showed a strong ability to replicate the SI 
value identified by more intense and costly fully-sampled 
methods. The DISTq-FS method performed in accordance 
with the previously published findings (Docherty et al. 2010). 
DISTq-S and DISTq-30 also correlated relatively well to the 
fully-sampled DIST, particularly compared to the well-
accepted HOMA. These results suggest that they could also 
be used as surrogate SI tests when there is a reduced 
resolution requirement, such as in preliminary T2DM or 
metabolic risk screening. The DISTq was not designed to 
identify Uen(t) and, as such, the resolution of these metrics 
was not sufficient to enable any beta-cell diagnostic value 
from these three tests. 
  
     
 
Most importantly, this spectrum of tests can be used in a 
hierarchy. In particular, the low-cost DISTq-S could be used 
in a metabolic risk screening programme. When a 
participant’s result is close to a diagnostic threshold, stored 
blood samples could be assayed for insulin and/or C-peptide. 
These added assays would cost more, but would enable 
identification from either the Sparse or Short protocol to find 
new, higher resolution SI and Uen(t), per Table 2. 
For example, if approximately 20% of a screening 
programme’s participants produce SI values close to a 
diagnostic threshold with the DISTq-S, the samples already 
obtained from the 20% of ambiguous tests could be re-
analysed using more assays to enable the Short protocol 
identification methods. Thus, a higher resolution more 
accurate result is achieved. With a sample cost of $12 for a 
DISTq-S and $312 for the Short protocol, the average sample 
cost per test for a programme with diagnostic resolution 
equivalent to the Short protocol would be $72/participant. 
This test evaluation was limited by the available data. Some 
such test evaluations are made with cross-over studies, which 
may include comparisons to gold standard tests. In this case, 
a self evaluation was used, wherein no inter-test repeatability 
was possible, and the results were thus potentially enhanced 
by the study design. In contrast, daily SI variations and assay 
errors did not reduce the correlations as they might in cross-
over, inter-protocol studies. 
Future investigations of alterations to the sampling regime 
could enhance the economy or information gained from the 
DISTq-styled protocols. If the glucose and insulin samples 
were combined, SI identification (with accuracy that is likely 
to be comparable to the DISTq-30) could be obtained from a 
single 20 minute test. Furthermore, if there were more time 
and samples between the glucose and insulin boluses, a 
patient-specific first-phase response to glucose could be 
estimated using only glucose data. However, these 
possibilities could not be investigated presently, as no such 
clinical data is yet available. 
5. Conclusion 
This article has presented a spectrum of tests from 
information rich, relatively frequently sampled, repeatable 
tests, to very sparsely sampled tests that produce limited 
information and moderate result accuracy. The accuracy and 
information available from dynamic tests is inherently linked 
to the cost in terms of protocol time, clinician intensity and 
assay cost. However, the results from the DIST-SI-2, Sparse 
and DISTq-30 protocols have shown that relatively high 
accuracy (R=0.92, R=0.89 and R=0.71 to the fully-sampled 
protocol respectively) is possible at the lower end of cost 
spectrum. 
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